Nontricyclic antidepressants: Predictors of nonadherence

Journal of Clinical Psychopharmacology

Volumn 26, Issue 6, 2006, Pages 643-647

  Brook, Oscar H ^a   Van Hout, Hein P J ^b   Stalman, Wim A B ^b   De Haan, Marten ^b  

^a Office of the Dutch Society for Surgery   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; CITALOPRAM; FLUOXETINE; FLUVOXAMINE; MIRTAZAPINE; PAROXETINE; SERTRALINE; VENLAFAXINE;

ADULT; ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DEPRESSION; DRUG HALF LIFE; DRUG SAFETY; EDUCATION; ELECTRONICS; FEMALE; FOLLOW UP; GENERAL PRACTITIONER; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL PATIENT; MULTIVARIATE ANALYSIS; PATIENT ATTITUDE; PATIENT COMPLIANCE; PATIENT MONITORING; PREDICTION; PRESCRIPTION; PRIORITY JOURNAL; SOCIAL SUPPORT; TREATMENT OUTCOME; UNIVARIATE ANALYSIS; UNSPECIFIED SIDE EFFECT;

EID: 33751092538     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Linden M, Gothe H, Dittmann RW, et al. Early termination of antidepressant drug treatment. J Clin Psychopharmacol. 2000;20:523-530.
2. Maidment R, Livingston G, Katona C. Just keep taking the tablets: adherence to antidepressant treatment in older people in primary care. Int J Geriatr Psychiatry. 2002;17:752-757.
3. Sleath B, Wurst K, Lowery T. Drug information sources and antidepressant adherence. Community Ment Health J. 2003;39:359-368.
4. Lingam R, Scott J. Treatment non-adherence in affective disorders. Acta Psychiatr Scand. 2002;105:164-172.
5. Demyttenaere K. Noncompliance with antidepressants: who's to blame? Int Clin Psychopharmacol. 1998;13(suppl 2):S19-S25.
6. DiMatteo MR, Lepper HS, Croghan TW. Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med. 2000;160:2101-2107.
7. Gonzalez J, Williams JW Jr, Noel PH, et al. Adherence to mental health treatment in a primary care clinic. J Am Board Fam Pract. 2005;18:87-96.
8. de Klerk E. Patient compliance with enteric-coated weekly fluoxetine during continuation treatment of major depressive disorder. J Clin Psychiatry. 2001;62(suppl 22):43-47.
9. Aikens JE, Nease DE Jr, Nau DP, et al. Adherence to maintenance-phase antidepressant medication as a function of patient beliefs about medication. Ann Fam Med. 2005;3:23-30.
10. Brook O, van Hout H, Nieuwenhuyse H, et al. Impact of coaching by community pharmacists on drug attitude of depressive primary care patients and acceptability to patients: a randomized controlled trial. Eur Neuropsychopharmacol. 2003;13:1-9.
11. Glyngdal P, Sorensen P, Kistrup K. Non-compliance in community psychiatry: failed appointments in the referral system to psychiatric outpatient treatment. Nord J Psychiatry. 2002;56:151-156.
12. Livianos-Aldana L, Vila-Gomez M, Rojo-Moreno L, et al. Patients who miss initial appointments in community psychiatry? A Spanish community analysis. Int J Soc Psychiatry. 1999;45:198-206.
13. Peeters FP, Bayer H. 'No-show' for initial screening at a community mental health centre: rate, reasons and further help-seeking. Soc Psychiatry Psychiatr Epidemiol. 1999;34:323-327.
14. Olfson M. Primary care patients who refuse specialized mental health services. Arch Intern Med. 1991;151:129-132.
15. Brook OH, Van Hout HP, Nieuwenhuysea H, et al. Effects of coaching by community pharmacists on psychological symptoms of antidepressant users: a randomised controlled trial. Eur Neuropsychopharmacol. 2003;13:347-354.
16. Brook OH, van Hout H, Stalman W, et al. A pharmacy-based coaching program to improve adherence to antidepressant treatment among primary care patients. Psychiatr Serv. 2005;56:487-489.
17. Urquhart J. The electronic medication event monitor. Lessons for pharmacotherapy. Clin Pharmacokinet. 1997;32:345-356.
18. Heerdink ER, Leufkens HG, Koppedraaijer C, et al. Information on drug use in the elderly: a comparison of pharmacy, general-practitioner and patient data. Pharm World Sci. 1995;17:20-24.
19. de Klerk E, van der HD, Landewe R, et al. The compliance-questionnaire- rheumatology compared with electronic medication event monitoring: a validation study. J Rheumatol. 2003;30:2469-2475.
20. Dietrich AJ, Oxman TE, Williams JW Jr, et al. Re-engineering systems for the treatment of depression in primary care: cluster randomised controlled trial. BMJ. 2004;329:602.
21. Derogatis LR, Lipman RS, Rickels K, et al. The Hopkins Symptom Checklist (HSCL). A measure of primary symptom dimensions. Mod Probl Pharmacopsychiatry. 1974;7:79-110.
22. Hogan TP, Awad AG, Eastwood R. A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychol Med. 1983;13:177-183.
23. PowerView [computer program]. Zug, Switzerland: Aardex Ltd; 1998.
24. Rosenbaum JF, Fava M, Hoog SL, et al. Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial. Biol Psychiatry. 1998;44:77-87.
25. Urquhart J, de Klerk E. Contending paradigms for the interpretation of data on patient compliance with therapeutic drug regimens. Stat Med. 1998;17:251-267.
26. Turner RJ, Marino F. Social support and social structure: a descriptive epidemiology. J Health Soc Behav. 1994;35:193-212.